Status:

TERMINATED

A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Lead Sponsor:

AbbVie

Collaborating Sponsors:

Merck Sharp & Dohme LLC

Conditions:

Cancer - Acute Myeloid Leukemia

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

An open-label, dose-escalation study to assess safety, pharmacokinetics and efficacy as well as determine the recommended Phase 2 doses of co-administered therapy of dinaciclib and venetoclax for pati...

Eligibility Criteria

Inclusion

  • Diagnosis of acute myeloid leukemia (AML) by World Health Organization criteria excluding acute promyelocytic leukemia (APL)-M3.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  • Participant must have adequate hematologic, renal, and liver function laboratory values as described in the protocol.

Exclusion

  • Known central nervous system leukemia
  • Severe chronic obstructive pulmonary disease (COPD) with hypoxemia
  • History of any malignancy within the last 6 months except for those specified in this protocol and low-grade malignancies not requiring active treatment.
  • Prior allogeneic stem cell transplant within 6 months of study drug administration and no requirement for graft versus host therapy.
  • History of clinically significant medical condition that, in the opinion of the investigator, would adversely affect participation in this study.
  • Known active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
  • History of tumor lysis syndrome (TLS) due to previous exposure to venetoclax.

Key Trial Info

Start Date :

July 23 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2022

Estimated Enrollment :

48 Patients enrolled

Trial Details

Trial ID

NCT03484520

Start Date

July 23 2018

End Date

December 1 2022

Last Update

December 30 2022

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

University of Arkansas /ID# 200016

Little Rock, Arkansas, United States, 72205

2

David Geffen School of Medicin /ID# 200015

Los Angeles, California, United States, 90095

3

The University ofChicago /ID# 200017

Chicago, Illinois, United States, 60637

4

University of Maryland School of Medicine /ID# 204015

Baltimore, Maryland, United States, 21201-1544